Tumor antigen escape, where cancer cells evade detection by altering or reducing the expression of target antigens, requires innovative solutions such as targeting multiple antigens simultaneously, combining ICEs with checkpoint inhibitors, and incorporating co-stimulatory molecules like 4-1BB and OX40 to strengthen immune responses and counteract resistance [89,90,91,92,93]. The gene discussed is TNFRSF9; the disease is cancer.